NZ332314A - Oral pharmaceutical preparation containing ibandronate or salts thereof in the form of an inner section containing the active ingredient surrounded by a coating free of the active ingredient - Google Patents

Oral pharmaceutical preparation containing ibandronate or salts thereof in the form of an inner section containing the active ingredient surrounded by a coating free of the active ingredient

Info

Publication number
NZ332314A
NZ332314A NZ332314A NZ33231497A NZ332314A NZ 332314 A NZ332314 A NZ 332314A NZ 332314 A NZ332314 A NZ 332314A NZ 33231497 A NZ33231497 A NZ 33231497A NZ 332314 A NZ332314 A NZ 332314A
Authority
NZ
New Zealand
Prior art keywords
active ingredient
ibandronate
salts
inner section
surrounded
Prior art date
Application number
NZ332314A
Other languages
English (en)
Inventor
Jorn Mockel
Rolf Dieter Gabel
Heinrich Woog
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7791961&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ332314(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Publication of NZ332314A publication Critical patent/NZ332314A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ332314A 1996-04-20 1997-04-21 Oral pharmaceutical preparation containing ibandronate or salts thereof in the form of an inner section containing the active ingredient surrounded by a coating free of the active ingredient NZ332314A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19615812A DE19615812A1 (de) 1996-04-20 1996-04-20 Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
PCT/EP1997/001940 WO1997039755A1 (de) 1996-04-20 1997-04-21 Orale pharmazeutische zubereitung enthaltend ibandronat

Publications (1)

Publication Number Publication Date
NZ332314A true NZ332314A (en) 2000-03-27

Family

ID=7791961

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ332314A NZ332314A (en) 1996-04-20 1997-04-21 Oral pharmaceutical preparation containing ibandronate or salts thereof in the form of an inner section containing the active ingredient surrounded by a coating free of the active ingredient

Country Status (26)

Country Link
US (2) US6143326A (enExample)
EP (2) EP1658852B1 (enExample)
JP (2) JP5037746B2 (enExample)
CN (1) CN101152160A (enExample)
AR (2) AR006652A1 (enExample)
AT (1) ATE404207T1 (enExample)
AU (1) AU722516B2 (enExample)
BR (1) BR9708785A (enExample)
CA (1) CA2251886C (enExample)
CO (1) CO4820394A1 (enExample)
CZ (1) CZ297341B6 (enExample)
DE (2) DE19615812A1 (enExample)
DK (1) DK0936913T4 (enExample)
ES (1) ES2313735T5 (enExample)
HU (1) HU228389B1 (enExample)
IL (2) IL163930A0 (enExample)
NO (1) NO319162B1 (enExample)
NZ (1) NZ332314A (enExample)
PA (1) PA8427301A1 (enExample)
PL (2) PL191910B1 (enExample)
PT (1) PT936913E (enExample)
RU (1) RU2193881C2 (enExample)
SI (1) SI0936913T2 (enExample)
TR (1) TR199802108T2 (enExample)
WO (1) WO1997039755A1 (enExample)
ZA (1) ZA973331B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19615812A1 (de) * 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
RU2193880C2 (ru) * 1997-06-11 2002-12-10 Дзе Проктер Энд Гэмбл Компани Покрытая пленкой таблетка улучшенной безопасности для верхних отделов желудочно-кишечного тракта
EP0998932A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
AR024462A1 (es) * 1999-07-01 2002-10-02 Merck & Co Inc Tabletas farmaceuticas
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6881420B2 (en) * 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
US6476006B2 (en) * 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
AU2001271055B2 (en) * 2000-07-17 2005-07-07 Astellas Pharma Inc. Pharmaceutical composition improved in peroral absorbability
JP2002332235A (ja) * 2001-02-01 2002-11-22 Riderway Corp 骨疾患治療用液体医薬組成物
AR034199A1 (es) * 2001-02-01 2004-02-04 Riderway Corp Composicion farmacologica liquida para el tratamiento de enfermedades oseas y procedimientos para su elaboracion
BR0209360A (pt) * 2001-05-02 2004-06-08 Novartis Ag Método de administração de bisfosfonatos por inalação no tratamento ou prevenção de reabsorção óssea e osteoporose
BR0206441A (pt) * 2001-12-19 2003-12-30 Astrazeneca Ab Composição de revestimento de pelìcula, revestimento de pelìcula cobrindo um núcleo farmacêutico, formulação farmacêutica de liberação modificada, e, processos para preparar uma composição de revestimento de pelìcula, um revestimento de pelìcula e uma formulação
NZ532994A (en) * 2001-12-21 2008-05-30 Procter & Gamble Method for the treatment of bone disorders using a bisphosphonate regimen, risedronate in particular
MXPA04008164A (es) 2002-02-21 2005-05-17 Biovail Lab Inc Formas de dosificacion de liberacion controlada.
CA2481142C (en) * 2002-05-10 2012-11-13 F.Hoffmann-La Roche Ag Bisphosphonic acids for the treatment and prevention of osteoporosis
GB0229258D0 (en) * 2002-12-16 2003-01-22 Boots Healthcare Int Ltd Medicinal compositions
NZ555514A (en) * 2002-12-20 2008-12-24 Hoffmann La Roche High dose ibandronate formulation
TR200300510A2 (tr) * 2003-04-18 2004-11-22 Sanovel �La� Sanay� Ve T�Caret A.�. Dağılan alendronat mikropartikül formülasyonu
RU2262923C2 (ru) * 2003-12-25 2005-10-27 Государственное образовательное учреждение высшего профессионального образования Курский государственный медицинский университет Министерства здравоохранения Российской Федерации Иммобилизованная форма доксорубицина
GB0403628D0 (en) * 2004-02-18 2004-03-24 Arrow Group Ltd Compression-coated tablets and the manufacture thereof
US20080286359A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645459B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US20080287400A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645460B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US8012949B2 (en) * 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
WO2006039721A2 (en) * 2004-10-08 2006-04-13 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
US20070191315A1 (en) * 2006-02-16 2007-08-16 Bengt Bergstrom Method for administering ibandronate
EP2001486A4 (en) * 2006-03-17 2010-12-29 Univ Illinois BIPHOSPHONATE COMPOUNDS AND CORRESPONDING METHODS
CN101495101B (zh) * 2006-07-25 2012-02-29 兴和株式会社 糖衣制剂及其制造方法
GB0616794D0 (en) 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
CA2570949A1 (en) * 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
WO2009075601A1 (fr) * 2007-12-12 2009-06-18 Alexander Valerievich Melnik Moyen d'indication d'une éventuelle prédisposition de chats à une maladie (variantes) et procédé de détermination de troubles de la santé chez les chats
EP2210596A1 (en) 2009-01-22 2010-07-28 Laboratorios Liconsa, S.A. Pharmaceutical composition of ibandronate sodium salt or a hydrate thereof
CN103079596B (zh) * 2010-08-31 2015-08-19 东丽株式会社 药物固体制剂用的包衣剂、药物用膜制剂以及包覆药物固体制剂
CA2839494C (en) * 2011-06-17 2018-11-06 Evonik Roehm Gmbh Coating composition suitable for pharmaceutical or nutraceutical dosage forms
RU2485957C1 (ru) * 2012-03-16 2013-06-27 Государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия последипломного образования" Министерства здравоохранения Российской Федерации (ГБОУ ДПО РМАПО Минздрава России) Средство для лечения низкообменного варианта заболевания скелета у больных с хронической почечной недостаточностью

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE965825C (de) 1949-10-30 1957-06-19 Walter Kloepfer Dipl Ing Dr In Zur Antennenebene senkrecht polarisierter Strahler
US4820698A (en) * 1985-11-04 1989-04-11 The Procter & Gamble Company Antimicrobial agents and process for their manufacture
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US5098717A (en) * 1987-12-09 1992-03-24 Thames Pharmacal Co., Inc. Method of treatment for pruritus
PH27186A (en) * 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
EP0550385A1 (de) * 1991-12-19 1993-07-07 Ciba-Geigy Ag Peroral zu verabreichende pharmazeutische Zusammensetzungen, die Methandiphosphonsäure-Derivate und 18-Krone-6 Ether enthalten
TW237386B (enExample) * 1992-04-15 1995-01-01 Ciba Geigy
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
RU2134103C1 (ru) * 1993-05-15 1999-08-10 Берингер Маннхайм ГмбХ Таблетка с улучшенной биодоступностью биологически активного вещества и вещество, повышающее биодоступность
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
DE19615812A1 (de) 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
US5803321A (en) * 1996-11-12 1998-09-08 Randy Hangers, Lll Hanger with ganging element
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery

Also Published As

Publication number Publication date
TR199802108T2 (xx) 1999-01-18
NO319162B1 (no) 2005-06-27
BR9708785A (pt) 1999-08-03
JP5557989B2 (ja) 2014-07-23
PL191363B1 (pl) 2006-05-31
ES2313735T5 (es) 2012-12-07
DK0936913T4 (da) 2012-11-19
ES2313735T3 (es) 2009-03-01
CZ297341B6 (cs) 2006-11-15
PT936913E (pt) 2008-09-25
WO1997039755A1 (de) 1997-10-30
HU228389B1 (en) 2013-03-28
HUP9903407A2 (hu) 2000-04-28
JP2000508673A (ja) 2000-07-11
CN101152160A (zh) 2008-04-02
NO984881L (no) 1998-10-19
RU2193881C2 (ru) 2002-12-10
AU2638297A (en) 1997-11-12
PA8427301A1 (es) 2002-07-30
AR054350A2 (es) 2007-06-20
JP2008285500A (ja) 2008-11-27
CA2251886C (en) 2008-06-17
EP0936913A1 (de) 1999-08-25
SI0936913T2 (sl) 2012-11-30
EP1658852B1 (de) 2016-11-09
HUP9903407A3 (en) 2000-11-28
AR006652A1 (es) 1999-09-08
DE19615812A1 (de) 1997-10-23
ZA973331B (en) 1998-10-19
NO984881D0 (no) 1998-10-19
AU722516B2 (en) 2000-08-03
JP5037746B2 (ja) 2012-10-03
EP0936913B2 (de) 2012-09-19
IL163930A0 (en) 2005-12-18
IL126655A0 (en) 1999-08-17
PL329347A1 (en) 1999-03-29
US6143326A (en) 2000-11-07
CO4820394A1 (es) 1999-07-28
ATE404207T1 (de) 2008-08-15
IL126655A (en) 2004-12-15
PL191910B1 (pl) 2006-07-31
CA2251886A1 (en) 1997-10-30
EP1658852A1 (de) 2006-05-24
EP0936913B1 (de) 2008-08-13
CZ336498A3 (cs) 2000-01-12
US20050089573A1 (en) 2005-04-28
DK0936913T3 (da) 2008-10-20
SI0936913T1 (sl) 2008-12-31
DE59712959D1 (de) 2008-09-25

Similar Documents

Publication Publication Date Title
NZ332314A (en) Oral pharmaceutical preparation containing ibandronate or salts thereof in the form of an inner section containing the active ingredient surrounded by a coating free of the active ingredient
RU2359678C2 (ru) Лекарственные формы на основе бисфосфонатов
US5853759A (en) Effervescent alendronate formulation
RU2381791C2 (ru) Лекарственные формы ризедроната
ES2255301T3 (es) Procedimiento para la preparacion de composiciones farmaceuticas orales que comprenden bisfosfonatos.
AU712710B2 (en) Effervescent bisphosphonate formulation
KR100307786B1 (ko) 이온교환제를포함하는메탄디포스폰산조성물
US20050026871A1 (en) Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin D derivative
TW200744673A (en) Improved ibandronate formulations
PL316987A1 (en) Biphosphonic acids containing preparation obtained by a wet granulation process
CA2454200A1 (en) Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate
YU31795A (sh) Oralne tečne formulacije alendronata
CA2149052A1 (en) Dry mix formulation for bisphosphonic acids
NZ556278A (en) Bisphosphonic acid for the treatment and prevention of osteoperosis
CA1294550C (en) Sustained release fluoride and calcium composition
GB2195245A (en) Sustained release fluoride composition
US20050142185A1 (en) Softgel formulations of bisphosphonates bone resorption inhibitors
EP1820497A2 (en) Effervescent bisphosphonate formulation
HK1108117A (en) Effervescent bisphosphonate formulation
EP1378234A1 (en) Effervescent bisphosphonate formulation
WO2003004008A3 (en) Pharmaceutical composition for prophylaxis and treatment of calcium metabolism disorders comprising clodronate in combination with glyceryl palmitostearate
AU6315499A (en) Effervescent bisphosphonate formulation
MXPA97004105A (en) Set for use in a therapeutic treatment cycle of osteoporo

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired